National Pharmaceutical Pricing Authority

Last updated

National Pharmaceutical Pricing Authority
Logo of National Pharmaceutical Pricing Authority.png
Agency overview
Formed29 August 1997 (1997-08-29)
Jurisdiction India
Headquarters3rd/5th Floor, YMCA Cultural Center Building 1, Jai Singh Road, New Delhi, India
Agency executive
  • Kamlesh Kumar Pant, Chairman
Parent departmentDepartment of Pharmaceuticals, Ministry of Chemicals and Fertilizers
Website nppaindia.nic.in

The National Pharmaceutical Pricing Authority (NPPA) is a government regulatory agency that controls the prices of pharmaceutical drugs in India. [1] National Pharmaceutical Pricing Authority (NPPA) was constituted vide Government of India Resolution dated 29 August 1997 as an attached office of the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers as an independent Regulator for pricing of drugs and to ensure availability and accessibility of medicines at affordable prices.

Contents

Drug Price Control Orders (DPCO)

The NPPA regularly publishes lists of medicines and their maximum selling prices. On 1 April 2022, NPPA increased prices of over 800 medicines under the National List of Essential Medicines (NELM) by over 10%. [2] the price increased was based on the Wholesale Price Index (WPI) data provided by the office of the Economic Advisor, Ministry of Commerce and Industry, the annual change in WPI works out as 10.76607% during the calendar year 2021 over the corresponding period in 2020. [3] The latest DPCO was released in 2013 and has a list of 384 drugs. [4] [5] [6] [7] [8] [9] On 4 December 2017, it was announced that a multi-disciplinary committee of experts for consultation on matters about the implementation of the Drug Price Control Order (DPCO) including technicalities involved in pricing and new launches will be set up and it will have a member secretary of the National Pharmaceutical Pricing Authority (NPPA) as its convener.

Functions

Initiatives

Price monitoring and resource unit (PMRU)

Under its program called "Consumer awareness, publicity and price monitoring (CAPPMS)" the NPPA has set up 12 Price monitoring and resource units in various States and UTs.It has planned to set up such units in all 36 states and UTs for better outreach of NPPA in the states as these units will help the NPPA and State drug controller to ensure the accessibility of drugs at affordable prices. The PMRUs are societies registered under The Societies Registration Act, 1860 under the direct supervision of The State Drug Controller with its "board of governors" containing nominees of state and central government apart from other stakeholders. They will be funded by NPPA for their recurring and non-recurring expenses. [12]

Related Research Articles

<span class="mw-page-title-main">Medication</span> Substance used to diagnose, cure, treat, or prevent disease

A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.

<span class="mw-page-title-main">Prescription drug</span> Medication legally requiring a medical prescription before it can be dispensed

A prescription drug is a pharmaceutical drug that is permitted to be dispensed only to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.

<span class="mw-page-title-main">Pharmaceutical industry</span> Industry involved with discovery, development, production and marketing of drugs

The pharmaceutical industry is an industry in medicine that discovers, develops, produces, and markets pharmaceutical drugs for use as medications to be administered to patients, with the aim to cure and prevent diseases, or alleviate symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy using drug testing and marketing of drugs. The global pharmaceuticals market produced treatments worth $1,228.45 billion in 2020 and showed a compound annual growth rate (CAGR) of 1.8%.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

An essential medicines policy is one that aims at ensuring that people get good quality drugs at the lowest possible price, and that doctors prescribe the minimum of required drugs in order to treat the patient's illness. The pioneers in this field were Sri Lanka and Chile.

The Sri Lanka National Pharmaceuticals Policy was established in the 1970s following the submission of a report by Dr S.A. Wickremasinghe and Prof. Seneka Bibile. It aimed at ensuring that people get good quality drugs at the lowest possible price and that doctors would prescribe the minimum required drugs to treat the patient's illness. It was a pioneer in the field of rational National pharmaceuticals policy.

<span class="mw-page-title-main">Essential medicines</span> WHO formulary

Essential medicines, as defined by the World Health Organization (WHO), are the medicines that "satisfy the priority health care needs of the population". These are the medications to which people should have access at all times in sufficient amounts. The prices should be at generally affordable levels. Since 1977, the WHO has published a model list of essential medicines, with the current (2019) list for adult patients containing over 400 medicines. Since 2007, a separate list of medicines intended for child patients has been published. Both the WHO adult and children's lists contain a notation indicating that a particular medication is "complementary", thus essentially there are two lists, the "core list" and the "complementary list". The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities are needed. In case of doubt medicines may also be listed as complementary on the basis of higher costs or less attractive cost-effectiveness in a variety of settings. The list is important because it forms the basis of national drugs policy in more than 155 countries, both in the developed and developing world. Many governments refer to WHO recommendations when making decisions on health spending. Countries are encouraged to prepare their own lists taking into consideration local priorities. Over 150 countries have published an official essential medicines list.

The pharmaceutical industry in Bangladesh is one of the most developed technology sectors within the country. Manufacturers produce insulin, hormones, and cancer drugs. This sector provides 97% of the total medicinal requirement of the local market. The industry also exports medicines to global markets, including Europe. Pharmaceutical companies are expanding their business with the aim to expand the export market.

Many developing nations have developed national drug policies, a concept that has been actively promoted by the WHO. For example, the national drug policy for Indonesia drawn up in 1983 had the following objectives:

Pharmaceutical policy is a branch of health policy that deals with the development, provision and use of medications within a health care system. It embraces drugs, biologics, vaccines and natural health products.

<span class="mw-page-title-main">Ministry of Chemicals and Fertilizers</span> Chemicals and Fertilizers in India

The Ministry of Chemicals and Fertilizers in India is the federal ministry with administrative purview over three departments namely:

Pharmacy in China involves the activities engaged in the preparation, standardization and dispensing of drugs, and its scope includes the cultivation of plants that are used as drugs, the synthesis of chemical compounds of medicinal value, and the analysis of medicinal agents. Pharmacists in China are responsible for the preparation of the dosage forms of drugs, such as tablets, capsules, and sterile solutions for injection. They compound physicians', dentists', and veterinarians' prescriptions for drugs. Pharmacological activities are also closely related to pharmacy in China.

A formulary is a list of pharmaceutical drugs, often decided upon by a group of people, for various reasons such as insurance coverage or use at a medical facility. Traditionally, a formulary contained a collection of formulas for the compounding and testing of medication. Today, the main function of a prescription formulary is to specify particular medications that are approved to be prescribed at a particular hospital, in a particular health system, or under a particular health insurance policy. The development of prescription formularies is based on evaluations of efficacy, safety, and cost-effectiveness of drugs.

<span class="mw-page-title-main">Ministry of National Health Services, Regulation and Coordination</span> Government of Pakistan executive body concerning health, human services

The Ministry of National Health Services, Regulation and Coordination is a cabinet level ministry of the government of Pakistan with responsibility for national public health.

Indian Drugs and Pharmaceuticals Limited (IDPL) is a public sector pharmaceutical, bulk drug manufacturing and drug discovery company owned by the Indian government, headquartered in New Delhi, and located in Hyderabad, Gurgaon and Rishikesh.: The company is involved in patent development alongside, National Institute of Pharmaceutical Education and Research to provide affordable drugs, and has recently released three over the counter drugs.

The pharmaceutical industry in Pakistan is strictly regulated by the Drug Regulatory Authority of Pakistan, which oversees drug approvals and pricing.

<span class="mw-page-title-main">Adrenocorticotropic hormone (medication)</span> Chemical compound

Adrenocorticotropic hormone is used as a medication and as diagnostic agent in the ACTH stimulation test.

Access to medicines refers to the reasonable ability for people to get needed medicines required to achieve health. Such access is deemed to be part of the right to health as supported by international law since 1946.

The distribution of medications has special drug safety and security considerations. Some drugs require cold chain management in their distribution.

<span class="mw-page-title-main">Federal Service for Surveillance in Healthcare</span>

Federal Service for Surveillance in Healthcare (Roszdravnadzor) is the federal service of the Russian Federation that exercises control and supervision functions in the field of health care. Until 2012, it was called the Federal Service for Surveillance of Health and Social Development and was subordinate to the Ministry of Health and Social Development of the Russian Federation, then from 2012 to 2020 it was shifted to reporting directly to the Government of the Russian Federation, and from 2020 again made subordinate to the Ministry of Health of the Russian Federation.

References

  1. "Regulator may permit rejig of pharma packaging cost". Business Standard . 28 May 2012. Retrieved 20 July 2014.
  2. Bhardwaj, Sameer. "Essential Medicines To Cost More Starting April". BloombergQuint. Retrieved 3 April 2022.
  3. Sharma, Priyanka (26 March 2022). "NPPA hikes prices of 800 essential drugs from 1 April". mint. Retrieved 3 April 2022.
  4. V, NALINAKANTHI (29 September 2014). "All you wanted to know about: DPCO". The Hindu Business Line. Retrieved 29 October 2017.
  5. "NOTIFIED PRICES OF BULK DRUGS AS SPECIFIED IN FIRST SCHEDULE OF DPCO,". www.nppaindia.nic.in. Retrieved 29 October 2017.
  6. "NOTIFIED PRICES OF BULK DRUGS AS SPECIFIED IN FIRST SCHEDULE OF DPCO,". www.nppaindia.nic.in. Retrieved 29 October 2017.
  7. "NOTIFIED PRICES OF BULK DRUGS AS SPECIFIED IN FIRST SCHEDULE OF DPCO,". www.nppaindia.nic.in. Retrieved 29 October 2017.
  8. "National Pharmaceutical Pricing Authority". www.nppaindia.nic.in. Retrieved 29 October 2017.
  9. "DPCO/NPPA | Department of Pharmaceuticals". pharmaceuticals.gov.in. Retrieved 29 October 2017.
  10. "Official National Pharmaceutical Pricing Authority".
  11. "National Pharmaceutical Pricing Authority (NPPA)". Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. Archived from the original on 28 July 2014. Retrieved 20 July 2014.
  12. "Price Monitoring and Resource Unit set up in Karnataka under the aegis of National Pharmaceutical Pricing Authority". Press Information bureau. Retrieved 2 September 2020.

http://nppaindia.nic.in/wh-new-2018/wh-new-07-2018.html "NPPA has fixed/revised ceiling prices/retail prices of 869 formulations under Drugs (Prices Control) Order, 2013 in related Notification /order dated 02.04.2018."